BioNTech Announces First Quarter 2025 Financial Results and Corporate Update
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: GlobeNewswire
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 20254 Full year 2025 financial guidance confirmed Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST) MAINZ, Germany, May 5, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq:
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA FieldGlobeNewswire
- BioNTech SE (BNTX) is a Buy on Lung Cancer Treatment Prospects: Clear Street [Yahoo! Finance]Yahoo! Finance
- BioNTech (NASDAQ:BNTX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- BioNTech (NASDAQ:BNTX) had its price target raised by analysts at Berenberg Bank from $150.00 to $155.00. They now have a "buy" rating on the stock.MarketBeat
- BioNTech (NASDAQ:BNTX) was upgraded by analysts at UBS Group AG to a "hold" rating.MarketBeat
BNTX
Earnings
- 11/3/25 - Miss
BNTX
Sec Filings
- 12/18/25 - Form 6-K
- 12/9/25 - Form 6-K
- 12/8/25 - Form 6-K
- BNTX's page on the SEC website